CAFs Targeted Ultrasound-Responsive Nanodroplets Loaded V9302 and GLULsiRNA to Inhibit Melanoma Growth via Glutamine Metabolic Reprogramming and Tumor Microenvironment Remodeling

Cancer-associated fibroblasts (CAFs) are critical for glutamine deprivation survival in melanoma. The authors assembled a CAFs-targeted, controlled-release nanodroplets for the combined delivery of the amino acid transporter ASCT2 inhibitor V9302 and GLULsiRNA.